Rivastigmine Tartrate dosage Reviews, Importers, Rivastigmine Tartrate dosage effects, Rivastigmine Tartrate drug dosage and interactions, apilist, Distributors, dosage Details, dosage warnings, dosage injection, bulk drugs suppliers, Rivastigmine Tartrate side effects, api, Generic Products dosage, Molecular Formula C14H22N2O2.C4H6O6, Molecular Weight 400.43,CAS Registry Number 129101-54-8, Rivastigmine Tartrate dosage, Exporters, Directory dosage, patient, Rivastigmine Tartrate dosage, Rivastigmine Tartrate dosage information by Taj Api

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Rivastigmine tartrate

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Rivastigmine Tartrate Manufacturers in India Suppliers Rivastigmine Tartrate Dossage Exporters Distributors Rivastigmine Tartrate api active pharmaceuticals ingredients Rivastigmine Tartrate manufacturers Side Effects bulk drugs raw material Dossage Rivastigmine Tartrate companies Side Effects Dossage Importers Rivastigmine Tartrate Dossage Rivastigmine Tartrate Exporters Rivastigmine Tartrate exporters Dossage FDA Dossage Rivastigmine Tartrate Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Rivastigmine Tartrate manufacturing pharmaceutical drugs pharmaceutical intermediates Rivastigmine Tartrate pharmaceutical chemicals pharmaceutical raw materials Rivastigmine Tartrate active pharmaceutical ingredients Rivastigmine Tartrate committee active pharmaceutical ingredients manufacturer Rivastigmine Tartrate Active Pharmaceutical Ingredients manufacturer Rivastigmine Tartrate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Rivastigmine Tartrate, Rivastigmine Tartrate manufacturer India, Rivastigmine Tartrate product, Rivastigmine Tartrate products, Api preparation, Certificate of Analysis API manufacturer product, Rivastigmine Tartrate anti ulcer product, Certificate of Origin COA Rivastigmine Tartrate COS Rivastigmine Tartrate, pharmaceutical generic, pharmaceutical drug, medical, Rivastigmine Tartrate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Rivastigmine Tartrate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Rivastigmine Tartrate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Rivastigmine Tartrate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Rivastigmine Tartrate ingredients, api, HIV Rivastigmine Tartrate, tablets, capsules, syrup & protein Rivastigmine Tartrate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Rivastigmine Tartrate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Rivastigmine Tartrate WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

manufacturing machine

HOME >> API >> API List 3 >> Rivastigmine Tartrate >> Dosage

DOSAGE
Rivastigmine Tartrate CAS Registry Number 129101-54-8

Rivastigmine Tartrate should be taken with food in the morning and in the evening.

* If you miss a dose...
Give the forgotten dose as soon as you remember. If it is almost time for the next dose, skip the one you missed and go back to the regular schedule. Never double the dose.

* Storage instructions...
Store at room temperature in a tightly closed container.

The dosage of Rivastigmine Tartrate (rivastigmine tartrate) shown to be effective in controlled clinical trials in Alzheimer's Disease is 6-12 mg/day, given as twice-a-day dosing (daily doses of 3 to 6 mg BID). There is evidence from the clinical trials that doses at the higher end of this range may be more beneficial.

The starting dose of Rivastigmine Tartrate is 1.5 mg twice a day (BID). If this dose is well tolerated, after a minimum of 2 weeks of treatment, the dose may be increased to 3 mg BID. Subsequent increases to 4.5 mg BID and 6 mg BID should be attempted after a minimum of 2 weeks at the previous dose. If adverse effects (e.g., nausea, vomiting, abdominal pain, loss of appetite) cause intolerance during treatment, the patient should be instructed to discontinue treatment for several doses and then restart at the same or next lower dose level. If treatment is interrupted for longer than several days, treatment should be reinitiated with the lowest daily dose and titrated as described above
The maximum dose is 6 mg BID (12 mg/day).

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE >>

SIDE EFFECTS

PRECAUTIONS

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.